Aurobindo Pharma AGM: All resolutions passed with overwhelming majority
Aurobindo Pharma's 39th AGM on August 27, 2026, saw all resolutions passed with high majority. Key approvals included financial statements for FY26, interim dividend of ₹4 per share, director reappointments, and secretarial auditor appointment. Shareholder turnout was strong, with overwhelming support for all proposals.
The announcement is a routine disclosure of AGM voting results, which are standard corporate governance procedures. While positive, it does not introduce new material information that would significantly impact the company's stock price or business operations.
All resolutions were passed with a requisite majority, indicating strong shareholder confidence and approval of the company's actions and financial reporting.
Aurobindo Pharma Limited announced the voting results of its 39th Annual General Meeting (AGM) held on August 27, 2026. All proposed resolutions were approved by the shareholders with a requisite majority. The AGM was conducted through Video Conferencing (VC) / Other Audio Visual Means (OAVM).
The resolutions included the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026, confirmation of the interim dividend of ₹4 per equity share for FY 2025-26, reappointment of Mr. K. Nithyananda Reddy and Dr. M. Madan Mohan Reddy as directors, and the appointment of M/s. RPR & Associates as Secretarial Auditors.
Detailed voting results, including e-voting and poll results, were submitted by the scrutinizer. For most resolutions, the votes in favour exceeded 99% of the votes polled, indicating strong shareholder support. The company confirmed that all disclosures and procedures were followed as per SEBI regulations.
A plain-language summary of a public exchange filing by Aurobindo Pharma Limited. Read the original for the full detail.